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Abstract
Objective: While most allergic responses to food are directed against protein epitopes and occur within 30
minutes of ingesting the allergen, recent studies suggest that delayed reactions may occur, sometimes mediated
by IgE antibodies directed against carbohydrate moieties. The objective of this review is to summarize the clinical
features and management of delayed hypersensitivity reactions to mammalian meat mediated by IgE antibodies to
galactose-alpha 1,3-galactose (alpha-gal), an oligosaccharide.
Methods: A PubMed search was conducted with MeSH terms: galactosyl-(1,3) galactose, oligosaccharides,
cetuximab, allergy/hypersensitivity, and anaphylaxis. Reported cases with alpha-gal-mediated reactions were
reviewed. This research study was approved by the Institutional Review Board of East Tennessee State University.
Results: Thirty-two cases of adults presenting with red-meat induced allergy thought to be related to
oligosaccharides have been reported in the literature so far, making this a rare and evolving syndrome. Most of
these patients demonstrated delayed reactions to beef, as was seen in the case reported by us in this manuscript.
IgE specific to alpha-gal was identified in most patients with variable response to skin testing with beef and pork.
Inhibition studies in some cases showed that the IgE antibodies to beef were directed towards alpha-gal in the
meat rather than the protein. The patients often reported history of tick bites, the significance of which is unclear
at present. Reactions to cetuximab, a monoclonal antibody, are mediated by a similar mechanism, with IgE
antibodies directed against an alpha-gal moiety incorporated in the drug structure.
Conclusion: Alpha-gal is an oligosaccharide recently incriminated in delayed anaphylactic reactions to mammalian
meats such as to beef, pork, and lamb. It appears that anaphylactic reactions to the anti-cancer biological agent,
cetuximab, may be linked mechanistically to the same process. More studies are required to understand the
underlying molecular basis for these delayed reactions in specific, and their broader implications for host defense
in general.
Keywords: Galactosyl-(1,3) galactose, Oligosaccharides, Cetuximab, Anaphylaxis, Food allergy, Delayed
hypersensitivity
Introduction
Beef Allergy and the New Evolving Syndrome
Food allergy remains a well-recognized problem that
affects people of different ages and can alter their qual-
ity of life [1,2]. Its prevalence and incidence seem to be
increasing over the past years [3-7] with more cases of
food-induced anaphylaxis being reported [8-11]. Food
hypersensitivity reactions are usually mediated by IgE
antibodies against the incriminated food allergens such
as eggs, seafood, milk, tree nuts, peanuts, wheat, soy,
and rarely beef (Additional file 1: Table S1) [8,10-13].
The development of IgE-mediated reaction to a food
that was well tolerated in the past sometimes constitutes
a true diagnostic and therapeutic challenge to the
patient and the physician [14]. The prevalence of food
allergy has been increasing, with up to 4% of children
having allergic reactions to one or more foods, of which
reactions to peanut, soy, wheat, and seafood are prob-
ably most common [8,10-15]. While clinical tolerance to
food allergens occurs in many children, some such as
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peanut and shell fish are characterized by the tenacity of
the sensitization and persistence of sensitivity into adult-
hood [12,13,15-17].
Among food allergies, hypersensitivity to red meat is
less common [18-22]. It was not adequately studied
until recently, with a few reports emphasizing the prob-
able cross reactivity between beef, cow’s milk, and other
types of red meat [23-31]. Some of the reactions,
referred to as “pork-cat syndrome”, involve cross-reac-
tivity between cat epithelial allergens and pork [32-39].
The presentations of allergic reactions to meat, as
reported in the literature, are reviewed in Additional file
2: Table S2. These include allergic reactions to meat
protein, oral allergy syndrome (food-pollen syndrome),
the pork-cat syndrome as explained earlier, and some
forms of exercise-induced anaphylaxis [18-41].
It was assumed that reactions to mammalian meats
would be immediate, and due to IgE directed against spe-
cific protein allergens such as bovine serum albumin
(BSA) [22,27,42-46]. However, over the past few years
investigators have described a new syndrome character-
ized by delayed reactions to mammalian meat associated
with IgE antibodies directed against oligosaccharides
[14,47,48]. Chung et al. first reported on IgE antibodies
specific to galactose-alpha 1,3-galactose (alpha-gal), an
oligosaccharide present in non-primates [49,50], when
studying allergic reactions in cancer patients treated with
cetuximab [51]. Commins et al. later reported on the role
of oligosaccharides and IgE antibodies to alpha-gal in
allergy to red meat [14,47,48]. This article will review 31
cases of delayed beef reactions from around the world
[18,48,52,53], along with one case from our clinic. It
summarizes the current understanding of this rare, novel,
and evolving syndrome.
Historical Perspectives in the Discovery of Alpha-gal-
mediated Allergy
Alpha-gal (Figure 1) is an oligosaccharide found in mam-
malian cells of non-primates [49,50]. The alpha-gal epi-
tope is present in beef, pork, lamb [14,47-49], and cat
dander [54,55], but is absent in chicken and fish [49].
Beta-galactosyl alpha 1,3 galactosyl transferase, the enzyme
needed for formation of alpha-gal, is inactivated in
humans and higher mammals due to an evolutionary pro-
cess. As a result, immunocompetent individuals may form
IgG isotype antibodies to alpha-gal [49,56]. These antibo-
dies contribute to immediate rejection of xenotransplants
such as with “pig organs” in humans (recipients). At the
same time, the high immunogenicity of alpha-gal may
allow for the generation of anti-viral vaccines, as well as
tumor vaccines that also carry the alpha-gal epitope [49].
Exposure to food allergens (including perhaps alpha-gal
in mammalian meat) results in the generation of IgG
antibodies from B cells and hence development of
immune tolerance. In predisposed individuals, due to
possible genetic/environmental factors (such as a fatty
diet, or tick bites), exposure of antigen presenting cells to
alpha-gal leads to Th2 activation and induction of inter-
leukins, leading to IgE formation by B cells. This culmi-
nates in mast cell activation, eosinophilia, and the full
gamut of IgE-mediated hypersensitivity reactions charac-
terized by urticaria, angioedema, and progression to sys-
temic anaphylaxis in some patients [8,57,58].
Cetuximab; Introduction, Infusion reactions, and Link to
Meat Allergy
Cetuximab is a recombinant chimeric epidermal growth
factor monoclonal antibody approved for treatment of
metastatic colorectal and head and neck cancer
[51,59-61]. Initial studies on cetuximab started in 2000,
when IMC-C225, was shown to inhibit the growth of
pancreatic cancer cells [62]. Further studies and clinical
trials on this monoclonal antibody, later given the name
cetuximab, were conducted [63-66]. It was shown that
cetuximab binds to tumor cells, and is able to activate
natural killer cells, eosinophils, and neutrophils to target
them against these cancer cells [67]. In 2004, cetuximab
was approved for the treatment of colon cancer (http://
www.fda.gov/NewsEvents/Newsroom/PressAnnounce-
ments/2004/ucm108244.htm) [59], and subsequently for
treatment of squamous cell head and neck cancer in
2006 (http://www.fda.gov/NewsEvents/Newsroom/Press-
Announcements/2006/ucm108609.htm). Since 2002,
cetuximab has induced severe hypersensitivity reactions
[51,68-70] that have led physicians to further study the
nature of these reactions, and determine the appropriate
management [71-73]. In 2007 and 2008, reports showed
that the infusion reactions were more prevalent in South-
eastern United States [51,68] (Figure 2A). This distribu-
tion is of interest, and may be related to other factors,
including diet as well as exposure to the Lone Star Tick
[74] (Figure 2B). In 2008, Chung et al. identified IgE anti-
bodies to alpha-gal in patients who developed mild to
severe allergic reactions, including anaphylaxis, following
treatment with cetuximab [51]. Then, in 2009, Commins
et al. reported on a similar geographic distribution of
patients presenting with delayed allergic reaction to red
meat, and studies were able to detect IgE to alpha-gal in
these patients as well [48]. More patients with this inter-
esting syndrome were further studied in Europe in 2009
and 2011 [18,52]. Figure 3 summarizes the chronological
events starting with the discovery of cetuximab, the aller-
gic reactions reported, the role of alpha-gal in these reac-
tions, and the link to red meat allergy.
The Cetuximab Hypersensitivity Syndrome
Reactions to biological agents (and most drugs) can be
classified as IgE and non-IgE mediated reactions, and
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can present in the form of skin, pulmonary, or cardiac
manifestations [77-79]. Non-IgE reactions may be sec-
ondary to cytokine release and/or tumor lysis syndrome
[80-84]. In the case of cetuximab, evidence suggests that
these reactions are IgE mediated and represent true
anaphylaxis.
As mentioned earlier, Chung et al. identified IgE anti-
bodies to alpha-gal in patients presenting with severe
infusion reactions to cetuximab [51]. In this series, the
authors reported on the presence of IgE antibodies
against cetuximab in sera from four groups of patients:
76 patients treated with cetuximab in the South-Eastern
United States, 72 healthy control subjects in Tennessee,
49 control subjects with cancer in California, 3 treated
with cetuximab, and 341 control subjects in Boston. The
authors show that 25/76 subjects treated with cetuximab
in Tennessee had clinical hypersensitivity to the drug,
and samples from 17 of those demonstrated IgE antibo-
dies to cetuximab, compared to only 1/51 in those
patients who did not have a hypersensitivity reaction.
The IgE antibodies were also found in 15/72 control
subjects in Tennessee and only in 3/49 samples in
Northern California and 2/341 control samples from
Boston. The studies showed that these IgE antibodies
are directed against the alpha-gal component of the Fab
fragment of cetuximab heavy chain (Figure 4) [51,85]. A
recent study by van Bueren et al. [85] reported the pre-
sence of alpha-gal epitopes in the Fc portion of several
monoclonal antibodies including infliximab, basiliximab,
palivizumab, panitumumab, and cetuximab. However,
only cetuximab was found to contain alpha-gal in the
Fab region of the heavy chain, and interestingly, was the
only drug able to bind to IgE specific to alpha-gal (Fig-
ure 4) [85]. IgE to alpha-gal failed to bind to the Fc por-
tion of the drugs due to several factors [85]. This might
explain the tolerance of some patients to panitumumab
after experiencing severe reactions to cetuximab [86-88].
Each cetuximab molecule contains two alpha-gal epi-
topes that can cross-link the high affinity receptor for
IgE (FcεRI) on mast cells [51]. IgE crosslinking of FcεRI
leads to activation of mast cells and degranulation with
release of hypersensitivity mediators including hista-
mine, prostaglandins, leukotrienes, tryptase, and cyto-
kines [57]. The possible mechanisms behind the
cetuximab reactions are demonstrated in cartoon format
in Figure 4.
Clinical Presentation and Diagnosis of Alpha-gal-related
Meat Allergy
The clinical presentation of alpha-gal-related red meat
allergy is similar to other food allergies, but has many
unique characteristics (Additional file 3: Table S3).
Upon presentation with suspected food allergy, history
taking remains the initial tool for diagnosis [12,18].
Patients with beef allergy related to alpha-gal have
symptoms that are common to other food induced
hypersensitivity reactions including urticaria, dyspnea,
hypotension, angioedema, or even full blown anaphylac-
tic shock [18,48,52,53], but with the caveat that reac-
tions occur hours after the ingestion of an incriminated
food. This sometimes makes the diagnosis difficult. A
detailed history including type of ingested foods, time to
onset of symptoms, the geographic area of residence as
well as history of tick bites, can help in achieving the
Figure 1 Structure of galactose-alpha 1,3-galactose (alpha-gal). Alpha-gal is an oligosaccharide found in mammalian cells of non-primates
[49,50]. The alpha-gal epitope is present in beef, pork, lamb [14,47-49], and cat dander [54,55], and absent in chicken and fish [49]. Beta-
galactosyl alpha 1,3 galactosyl transferase, the enzyme needed for formation of alpha-gal, is inactivated in humans and higher mammals [49,56].
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Figure 2 Areas in USA where IgE to alpha-gal is common and the associated tick. A: Map of United States of America with highlights on
the south-eastern region in which reactions to cetuximab [51], as well as seropositivity to alpha-gal in delayed red meat allergy [48], are most
prevalent. B: Lone star tick (Amblyomma americanum), most prevalent in southeast USA and linked to alpha-gal allergy [74-76]. Image used with
permission from Iowa State University Entomology department; Credit to John VanDyk.
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diagnosis. A patient presenting from the South-Eastern
United States with allergy to red meat occurring up to
3-7 hours after ingestion, and with a history of tick
bites, would be suggestive of alpha-gal allergy.
In general, confirming the diagnosis of a specific food
allergy has many components. Although food challenges
remain the “gold standard” for definitive diagnosis
[12,13], most physicians would start with basic tests
including skin prick test (SPT), intradermal testing, or
patch testing with the suspected allergen. In some cases
where skin tests could not be performed, serum IgE anti-
body quantification for the suspected allergen/s is safe
and easy [12], but there is high number of false positive
results, and the IgE level does not necessarily correlate
with the severity of the reaction [8,12]. The approach to
delayed food reactions however has some caveats. A food
challenge may be unnecessary if the history and serologi-
cal tests are confirmatory, and may in fact be dangerous.
Figure 3 The events in the understanding of cetuximab and Alpha-gal-mediated hypersensitivity. With the use of cetuximab in
treatment of head and neck cancer and colorectal carcinoma, multiple infusion reactions were reported. Chung el al. in 2008 were able to
identify IgE to alpha-gal directed to the Fab portion of cetuximab and was related to the allergic reactions. IgE to alpha-gal was later linked to
allergic reactions to red meat in America and Europe. Information from references: [18,51,52,59-74].
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Food challenges are best conducted in research environ-
ments and their role is yet to be defined in the delayed
reactions to mammalian meats.
In the USA, Commins et al. at University of Virginia
Health System are the leaders in studying delayed red
meat allergy [14,47,48]. They studied 24 patients with
IgE to alpha-gal [48]: 4 initially presented with hyper-
sensitivity to beef, 15 identified from a cohort study of
243 patients, and 5 presenting from a clinic in Missouri.
All 24 patients had delayed allergic reactions after
Figure 4 The possible mechanism behind cetuximab induced allergies. Cetuximab is a recombinant chimeric epidermal growth factor
monoclonal antibody approved for treatment of metastatic colorectal and head and neck cancer [51,59-61]. Infusion reactions with cetuximab
are linked to the presence of IgE antibodies directed against the alpha-gal component of the Fab fragment of cetuximab heavy chain [51,85].
Each cetuximab molecule contains two alpha-gal epitopes that can cross-link the high affinity receptor for IgE (FcεRI) on mast cells [51] leading
to mast cell activation and release of hypersensitivity mediators [57].
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ingestion of red meat. Patients were between the ages of
18 and 80 years, 14 males and 10 females, and present-
ing from southeast United States. In addition to IgE to
alpha-gal, total IgE levels, and IgE to beef were mea-
sured in the studied cases. 22 out of 24 patients had
positive (> 0.35 IU/ml) IgE to beef with variable total
IgE levels. Skin testing was performed on 18 patients
using both commercial and fresh beef extracts, 13 of
which gave positive results. 10 patients had intradermal
testing to beef and all gave positive results. Although
more than 72% of patients had positive SPT to beef and
100% of tested patients had positive intradermal tests to
beef, Commins reported that these reactions were not
impressive when compared to the IgE to beef, and the
severity of reactions they experienced [48]. Studies
showed that fresh extracts of beef and pork contain
more alpha-gal amounts than commercial extracts, and
hence were able to produce better results [18,48]. This
is no surprise as multiple reports showed that the aller-
genicity of beef changes with the method of processing
and heat exposure [26,89-92]. The source of meat and
the preparation of the extract used in SPT differ
between laboratories and even countries. This indeed
can attribute to the variability of results in each study.
Almost 80% of the studied patients in Commins paper
had no further symptoms of hypersensitivity reactions
after avoidance of red meat. The others had fewer mani-
festations. Detailed information of the involved patients
and their laboratory results is outlined in Commins and
Platts-Mills original paper [48].
Seven other patients studied in Europe presented with
delayed allergy to red meat, and had IgE levels positive
for alpha-gal and beef [18,52]. In France, investigations
on two patients showed mild SPT reactions to raw beef
and pork, but significant skin reaction when tested with
cetuximab, even with low concentrations [18]. Nunez et
al. in Spain also reported on 5 patients with IgE antibo-
dies specific to alpha-gal, all presenting with severe red
meat allergy. All five patients tested positive for IgE to
beef, pork, lamb, and rabbit. SPT with raw beef and
cetuximab were positive in all five as well [52]. Other
cases with similar history and presentation to alpha-gal
allergy were reported, but to our knowledge testing for
alpha-gal was not conducted [14,53]. Clinical presenta-
tions of cases with alpha-gal allergy and variable diagnos-
tic tests are summarized in Additional file 4: Table S4.
A 48-year old male patient with delayed reaction to
beef presented to our clinic in East Tennessee. He
experienced recurrent urticarial eruptions (Figure 5A)
and dyspnea that occurred 5 to 7 hours after red meat
ingestion, including beef and pork. Interestingly, the
patient reported a history of tick bites 2 weeks prior to
his first reaction. Initial blood work showed negative IgE
levels to beef and pork, but repeated testing of the same
sample was positive to beef. He also had very elevated
levels of IgE specific to alpha-gal. Our patient now
avoids red meat products and has not experienced any
further reactions with food ingestion. Additional labora-
tory data and information is summarized in Additional
file 4: Table S4 and Figure 5B.
The Presumed Role of Tick Bites
Although genetic factors may predispose an individual
to develop an allergic reaction to beef, Commins pro-
vided strong evidence that tick bites likely play an
important role in this development [48,74]. Bites from
the tick species Amblyomma americanum (Lone Star
tick (Figure 2B)), commonly found in the south east and
south central areas of the United States [75], seem to
precede the hypersensitivity to alpha-gal[74]. This phe-
nomenon suggests a role in the sensitization process.
The bite of the lone star tick is associated with the
development of STARI [76] (southern tick-associated rash
illness) usually typified by a large “bulls eye” skin lesion
and accompanied by fever, myalgia, and arthralgia. It is
important to differentiate this illness from lime disease
[76]. How instrumental tick bites are in alpha-gal sensiti-
zation, and the mechanism by which this occurs is still
unclear.
In a recent study, Commins and James reviewed three
patients with known IgE levels to alpha-gal, and documen-
ted a significant elevation in these levels after exposure to
tick bites [74]. A strong correlation between antibodies to
Amblyomma americanum and those to alpha-gal was pre-
sent. Additionally, they screened several individuals and
found that most of those whose serum tested positive for
alpha-gal, provided a history of tick bites, irrespective of
whether they had developed meat reactions [74].
In other areas of the world, history of tick bites (differ-
ent than Amblyomma americanum) is associated with
development of meat-induced allergy [52,53]. In a study
by Van Nunen in Sydney Australia [53], almost all
patients (24/25) presenting with the red meat allergy
gave a history of tick bites. The suspected tick is Ixodes
holocyclus [53], mainly distributed in southeastern Aus-
tralia [93], and is associated with severe paralysis and car-
diovascular problems [94-98]. In Spain 4 of 5 patients
with meat allergy expressed history of tick bites prior to
the reaction [52]. Although no documented proof of the
tick species related to these reactions, the tick common
in that area in Spain (north-western) is Ixodes ricinus
[52]. Cases with reported history of tick bites and the sus-
pected tick are summarized in Additional file 4: Table S4.
Relationship to Dietary Fat and the Presumed Mechanism
of Delay
Another interesting relationship between the areas
where alpha-gal allergy is reported in the United States
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is the obesity rate. The recently reported obesity rates
from the Center of Disease Control and Prevention for
Tennessee, Arkansas, and North Carolina were higher
than those in California and Massachusetts, areas where
alpha-gal allergy is uncommon [51]. This raises the
question of whether high-fat consumption in diet can be
an additional reason for geographical alpha-gal IgE
distribution.
The mechanism behind the delayed presentation of
symptoms after red meat ingestion in patients with IgE
to alpha-gal is still undetermined. A possible explanation
suggested by Commins et al. proposes this delay to the
time needed for red meat to be digested and presented
to circulation [48]. Lipid and glycolipid complexes may
mediate delayed absorption and presentation of alpha-
gal to antigen presenting cells [14,48]. It only takes
about 2 hours for glucose to reach its maximum level in
the plasma after a meal. In contrast, it takes about 4-5
hours for dietary triglycerides to reach their peak in cir-
culation [99,100]. In the postprandial state, dietary tri-
glycerides are packaged in the small intestine into very-
low density lipoproteins (VLDLs) and chylomicrons, two
of the largest lipoprotein particles [101]. Due to their
large size, VLDLs (30-80 nm in diameter) and chylomi-
crons (> 80 nm in diameter) are driven to enter the
lymphatic circulation before being emptied into the
venous circulation via the subclavian vein. Soluble diet-
ary nutrients, such as amino acids and glucose, directly
enter the venous circulation via the superior mesenteric
vein/hepatic portal vein. On the other hand, insoluble
dietary nutrients including long-chain triglycerides,
cholesterol, and lipid-soluble vitamins are packaged by
the small intestine into VLDLs and chylomicrons for
transport through the lymphatic circulation [102].
Alpha-gal is known to be abundantly present on glyco-
lipids and glycoproteins of non-primate mammals,
including the red meat from beef, pork, and lamb [49,50].
Glycolipids and glycoproteins need to be digested in the
intestinal lumen before they can be taken up by entero-
cytes. These alpha-gal-containing digestion products are
likely lipid soluble and expected to be transported in
VLDLs and/or chylomicrons [48]. The delay of both the
allergic reaction and the peak of dietary triglycerides in
the circulation, suggests that the allergen from red meat
is transported together with dietary triglycerides [48].
Since lipoproteins are made out of a phospholipid mono-
layer, the alpha-gal containing glycolipids may be
inserted into the phospholipid monolayer with the carbo-
hydrate group facing towards the exterior. The “exposed”
orientation, rather than “buried”, should be optimal for
inducing an allergic reaction. Studies should be aimed
towards determining the presence of alpha-gal in intest-
inal lipoproteins. The presence of alpha-gal should only
be detected in VLDL/chylomicron fractions from inges-
tion of red meat from non-primate mammals, and not
from other dietary sources, e.g., chicken and vegetarian
meals.
Food Anaphylaxis and Hypersensitivity Reaction
Management
The delay in appearance of symptoms related to alpha-
gal allergy makes it difficult for patients and physicians
Figure 5 Urticarial eruptions (A) and laboratory data (B) in a patient with alpha-gal related red meat allergy. A 48 year-old patient
presented with recurrent urticarial eruptions and dyspnea 5 to 7 hours after red meat ingestion. Patient reported history of tick bites 2 weeks
prior to his first reaction. Initial workup showed negative IgE to beef and pork. SPT to beef was not performed. Repeated testing was positive to
beef and alpha-gal. Patient avoids red meat products and symptoms are well controlled.
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to identify the trigger [14]. If such an event were to
occur, the patient would be advised to go to the nearest
hospital or emergency room. Once the diagnosis is sus-
pected on the basis of history and epidemiological set-
ting, appropriate testing should be done to confirm the
diagnosis. Following this, preventive measures include
avoidance of red meat and the use of injectable epi-
nephrine [40,48,58,103]. Education and instruction on
use of injectable epinephrine is vital. Acute management
of patients presenting with anaphylaxis, including those
related to alpha-gal, is summarized in Additional file 5:
Table S5.
Conclusion
Alpha-gal allergy is a new and evolving syndrome
related to oligosaccharides, rather than protein, in red
meat. The IgE mediated response to alpha-gal tends to
occur several hours after antigen exposure. This unique
presentation constitutes a challenge to both patients and
physicians, making detailed history very important if
suspected. Reactions to cetuximab seem to be mediated
by an identical mechanism. More studies are required
about this unique syndrome, including an explanation
for the mechanism of delay in presentation and the pos-
sible roles obesity and tick bites play in the predisposi-
tion for the disorder.
Additional material
Additional file 1: Table 1. Common food allergens.
Additional file 2: Table 2. Meat Allergy Types and Features.
Additional file 3: Table 3. Diagnostic features of alpha-gal-related food
allergy.
Additional file 4: Table 4. Summary of reported cases with alpha-gal
allergy in USA and Europe.
Additional file 5: Table 5. Acute Management and Prevention of
Anaphylaxis*.
Abbreviations
Alpha-gal: Galactose-alpha 1,3-galactose; BSA: Bovine serum albumin; SPT:
Skin-prick test; FEIA: Fluorescence enzyme immunoassay; VLDLs: Very-low
density lipoproteins; FDEIA: Food-dependent exercise-induced anaphylaxis;
OSA: Ovine serum albumin.
Author details
1Department of Internal Medicine, Division of Allergy and Clinical
Immunology, Quillen College of Medicine, East Tennessee State University, P.
O. Box 70622, Johnson City, Tennessee 37614-0622, USA. 2Division of Health
Sciences, East Tennessee State University, Johnson City, Tennessee, USA.
Authors’ Contributions
HS reviewed the literature, generated references, organized the manuscript,
and illustrated the figures. SE assisted with manuscript review and
corrections. AN assisted in section involving mechanism of delay and role of
chylomicrons. SA assisted in section involving mechanism of delay and role
of chylomicrons. GK organized the manuscript, edited figures and tables,
assisted in discussion, generated references, and participated in the editing
and final approval of the manuscript. All authors read and approved the
final manuscript.
Competing Interests
The authors declare that they have no competing interests.
Received: 14 November 2011 Accepted: 7 March 2012
Published: 7 March 2012
References
1. Lieberman JA, Sicherer SH: Quality of life in food allergy. Curr Opin Allergy
Clin Immunol 2011, 11(3):236-242.
2. Amrol DJ: Food allergy: an overdiagnosed but underappreciated
problem. South Med J 2011, 104(5):308.
3. Venter C, Arshad SH: Epidemiology of food allergy. Pediatr Clin North Am
2011, 58(2):327-349, ix.
4. Boyce JA, Assa’a A, Burks AW, et al: Guidelines for the diagnosis and
management of food allergy in the United States: summary of the
NIAID-Sponsored Expert Panel Report. Nutrition 2011, 27(2):253-267.
5. Boyce JA, Assa’ad A, Burks AW, et al: Guidelines for the diagnosis and
management of food allergy in the United States: report of the NIAID-
sponsored expert panel. J Allergy Clin Immunol 2010, 126(6 Suppl):S1-S58.
6. Koplin JJ, Martin PE, Allen KJ: An update on epidemiology of anaphylaxis
in children and adults. Curr Opin Allergy Clin Immunol 2011, 11(5):492-496.
7. Sicherer SH: Food allergy. Mt Sinai J Med 2011, 78(5):683-696.
8. Lee JK, Vadas P: Anaphylaxis: mechanisms and management. Clin Exp
Allergy 2011, 41(7):923-938.
9. Keet C: Recognition and management of food-induced anaphylaxis.
Pediatr Clin North Am 2011, 58(2):377-388, x.
10. Jarvinen KM: Food-induced anaphylaxis. Curr Opin Allergy Clin Immunol
2011, 11(3):255-261.
11. Food allergies and food intolerances. Both are on the rise–and it’s
important to know the difference. Harv Womens Health Watch 2011,
18(9):4-6.
12. Siles RI, Hsieh FH: Allergy blood testing: a practical guide for clinicians.
Cleve Clin J Med 2011, 78(9):585-592.
13. Kurowski K, Boxer RW: Food allergies: detection and management. Am
Fam Physician 2008, 77(12):1678-1686.
14. Commins SP, Platts-Mills TA: Allergenicity of carbohydrates and their role
in anaphylactic events. Curr Allergy Asthma Rep 2010, 10(1):29-33.
15. Husain Z, Schwartz RA: Peanut allergy: an increasingly common life-
threatening disorder. J Am Acad Dermatol 2011, 66(1):136-143.
16. Ho MH, Wong WH, Heine RG, et al: Early clinical predictors of remission of
peanut allergy in children. J Allergy Clin Immunol 2008, 121(3):731-736.
17. Sicherer SH, Munoz-Furlong A, Sampson HA: Prevalence of peanut and
tree nut allergy in the United States determined by means of a random
digit dial telephone survey: a 5-year follow-up study. J Allergy Clin
Immunol 2003, 112(6):1203-1207.
18. Jacquenet S, Moneret-Vautrin DA, Bihain BE: Mammalian meat-induced
anaphylaxis: clinical relevance of anti-galactose-alpha-1,3-galactose IgE
confirmed by means of skin tests to cetuximab. J Allergy Clin Immunol
2009, 124(3):603-605.
19. Orhan F, Sekerel BE: Beef allergy: a review of 12 cases. Allergy 2003,
58(2):127-131.
20. Theler B, Brockow K, Ballmer-Weber BK: Clinical presentation and
diagnosis of meat allergy in Switzerland and Southern Germany. Swiss
Med Wkly 2009, 139(17-18):264-270.
21. Kim JH, An S, Kim JE, et al: Beef-induced anaphylaxis confirmed by the
basophil activation test. Allergy Asthma Immunol Res 2010, 2(3):206-208.
22. Fuentes MM, Palacios R, Garces MM, Caballero ML, Moneo I: Isolation and
characterization of a heat-resistant beef allergen: myoglobin. Allergy
2004, 59(3):327-331.
23. Mamikoglu B: Beef, pork, and milk allergy (cross reactivity with each
other and pet allergies). Otolaryngol Head Neck Surg 2005, 133(4):534-537.
24. Eigenmann PA: Anaphylaxis to cow’s milk and beef meat proteins. Ann
Allergy Asthma Immunol 2002, 89(6 Suppl 1):61-64.
25. Martelli A, De CA, Corvo M, Restani P, Fiocchi A: Beef allergy in children
with cow’s milk allergy; cow’s milk allergy in children with beef allergy.
Ann Allergy Asthma Immunol 2002, 89(6 Suppl 1):38-43.
26. Werfel SJ, Cooke SK, Sampson HA: Clinical reactivity to beef in children
allergic to cow’s milk. J Allergy Clin Immunol 1997, 99(3):293-300.
Saleh et al. Clinical and Molecular Allergy 2012, 10:5
http://www.clinicalmolecularallergy.com/content/10/1/5
Page 9 of 11
27. Fuentes AV, Sanchez MI, Perez MA, Baeza ML, de Barrio FM: Allergy to
mammal’s meat in adult life: immunologic and follow-up study. J Investig
Allergol Clin Immunol 2005, 15(3):228-231.
28. Restani P, Beretta B, Fiocchi A, Ballabio C, Galli CL: Cross-reactivity between
mammalian proteins. Ann Allergy Asthma Immunol 2002, 89(6 Suppl
1):11-15.
29. Vicente-Serrano J, Caballero ML, Rodriguez-Perez R, et al: Sensitization to
serum albumins in children allergic to cow’s milk and epithelia. Pediatr
Allergy Immunol 2007, 18(6):503-507.
30. Restani P, Ballabio C, Tripodi S, Fiocchi A: Meat allergy. Curr Opin Allergy
Clin Immunol 2009, 9(3):265-269.
31. San-Juan S, Lezaun A, Caballero ML, Moneo I: Occupational allergy to raw
beef due to cross-reactivity with dog epithelium. Allergy 2005,
60(6):839-840.
32. Savi E, Rossi A, Incorvaia C: Cat-pork syndrome: a case report with a thee
years follow-up. Eur Ann Allergy Clin Immunol 2006, 38(10):366-368.
33. Drouet M, Sabbah A, Le SJ, et al: Fatal anaphylaxis after eating wild boar
meat in a patient with pork-cat syndrome. Allerg Immunol (Paris) 2001,
33(4):163-165.
34. Couturier P, Basset-Stheme S, Sainte-Laudy J: [Pork-cat syndrome in a 16-
month-old child]. Allerg Immunol (Paris) 1999, 31(2):60.
35. Drouet M, Sabbah A: The pork/cat syndrome or crossed reactivity
between cat epithelia and pork meat. Monogr Allergy 1996, 32:164-173.
36. Drouet M, Lauret MG, Sabbah A: [The pork-cat syndrome: effect of
sensitization to cats on sensitization to pork meat. Apropos of a case].
Allerg Immunol (Paris) 1994, 26(8):305-306.
37. Drouet M, Lauret MG, Sabbah A: [The pork-cat syndrome: effect of
sensitivity to cats on that to pork meat. Based on an observation]. Allerg
Immunol (Paris) 1994, 26(7):261-262.
38. Sabbah A, Rousseau C, Lauret MG, Drouet M: The pork-cat syndrome:
RAST inhibition test with Feld One. Allerg Immunol (Paris) 1994,
26(7):259-260.
39. Drouet M, Boutet S, Lauret MG, et al: The pork-cat syndrome or crossed
allergy between pork meat and cat epithelia (1). Allerg Immunol (Paris)
1994, 26(5):166-168, 171-172.
40. Miller CW, Guha B, Krishnaswamy G: Exercise-induced anaphylaxis: a
serious but preventable disorder. Phys Sportsmed 2008, 36(1):87-94.
41. Biedermann T, Schopf P, Rueff F, Przybilla B: Exertion-induced anaphylaxis
after eating pork and beef. Dtsch Med Wochenschr 1999, 124(15):456-458.
42. Fiocchi A, Restani P, Riva E: Beef allergy in children. Nutrition 2000,
16(6):454-457.
43. Fiocchi A, Restani P, Bouygue GR, Martelli A: Beef allergy in adults and
children. Allergy 2005, 60(1):126.
44. Ohmori K, Masuda K, Kawarai S, et al: Identification of bovine serum
albumin as an IgE-reactive beef component in a dog with food
hypersensitivity against beef. J Vet Med Sci 2007, 69(8):865-867.
45. Han GD, Matsuno M, Ito G, Ikeucht Y, Suzuki A: Meat allergy: investigation
of potential allergenic proteins in beef. Biosci Biotechnol Biochem 2000,
64(9):1887-1895.
46. Tanabe S, Shibata R, Nishimura T: Hypoallergenic and T cell reactive
analogue peptides of bovine serum albumin, the major beef allergen.
Mol Immunol 2004, 41(9):885-890.
47. Commins SP, Platts-Mills TA: Anaphylaxis syndromes related to a new
mammalian cross-reactive carbohydrate determinant. J Allergy Clin
Immunol 2009, 124(4):652-657.
48. Commins SP, Satinover SM, Hosen J, et al: Delayed anaphylaxis,
angioedema, or urticaria after consumption of red meat in patients with
IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin
Immunol 2009, 123(2):426-433.
49. Macher BA, Galili U: The Galalpha1, 3Galbeta1, 4GlcNAc-R (alpha-Gal)
epitope: a carbohydrate of unique evolution and clinical relevance.
Biochim Biophys Acta 2008, 1780(2):75-88.
50. Christiane Y, Aghayan M, Emonard H, et al: Galactose alpha 1-3 galactose
and anti-alpha galactose antibody in normal and pathological
pregnancies. Placenta 1992, 13(5):475-487.
51. Chung CH, Mirakhur B, Chan E, et al: Cetuximab-induced anaphylaxis and
IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008,
358(11):1109-1117.
52. Nunez R, Carballada F, Gonzalez-Quintela A, et al: Delayed mammalian
meat-induced anaphylaxis due to galactose-alpha-1,3-galactose in 5
European patients. J Allergy Clin Immunol 2011, 128(5):1122-1124.
53. Van Nunen SA, O’Connor KS, Clarke LR, Boyle RX, Fernando SL: An
association between tick bite reactions and red meat allergy in humans.
Med J Aust 2009, 190(9):510-511.
54. Gronlund H, Adedoyin J, Commins SP, Platts-Mills TA, van HM: The
carbohydrate galactose-alpha-1,3-galactose is a major IgE-binding
epitope on cat IgA. J Allergy Clin Immunol 2009, 123(5):1189-1191.
55. Arkestal K, Sibanda E, Thors C, et al: Impaired allergy diagnostics among
parasite-infected patients caused by IgE antibodies to the carbohydrate
epitope galactose-alpha 1,3-galactose. J Allergy Clin Immunol 2011,
127(4):1024-1028.
56. Hamadeh RM, Jarvis GA, Zhou P, Cotleur AC, Griffiss JM: Bacterial enzymes
can add galactose alpha 1,3 to human erythrocytes and creates a
senescence-associated epitope. Infect Immun 1996, 64(2):528-534.
57. Khan BQ, Kemp SF: Pathophysiology of anaphylaxis. Curr Opin Allergy Clin
Immunol 2011, 11(4):319-325.
58. Krishnaswamy G, Ajitawi O, Chi DS: The human mast cell: an overview.
Methods Mol Biol 2006, 315:13-34.
59. Cetuximab approved by FDA for treatment of head and neck squamous
cell cancer. Cancer Biol Ther 2006, 5(4):340-342.
60. Wong SF: Cetuximab: an epidermal growth factor receptor monoclonal
antibody for the treatment of colorectal cancer. Clin Ther 2005,
27(6):684-694.
61. Blick SK, Scott LJ: Cetuximab: a review of its use in squamous cell
carcinoma of the head and neck and metastatic colorectal cancer. Drugs
2007, 67(17):2585-2607.
62. Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ: Epidermal
growth factor receptor blockade by antibody IMC-C225 inhibits growth
of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000,
89(1):74-82.
63. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal
growth factor receptor chimeric antibody C225 alone and in
combination with cisplatin. J Clin Oncol 2000, 18(4):904-914.
64. Maubec E, Petrow P, Scheer-Senyarich I, et al: Phase II study of cetuximab
as first-line single-drug therapy in patients with unresectable squamous
cell carcinoma of the skin. J Clin Oncol 2011, 29(25):3419-3426.
65. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al: Phase II trial of cetuximab in
patients with refractory colorectal cancer that expresses the epidermal
growth factor receptor. J Clin Oncol 2004, 22(7):1201-1208.
66. Argiris A, Feinstein TM, Wang L, et al: Invest New Drugs: phase I and
pharmacokinetic study of dasatinib and cetuximab in patients with
advanced solid malignancies. 2011.
67. Patel D, Guo X, Ng S, et al: IgG isotype, glycosylation, and EGFR
expression determine the induction of antibody-dependent cellular
cytotoxicity in vitro by cetuximab. Hum Antibodies 2010, 19(4):89-99.
68. O’Neil BH, Allen R, Spigel DR, et al: High incidence of cetuximab-related
infusion reactions in Tennessee and North Carolina and the association
with atopic history. J Clin Oncol 2007, 25(24):3644-3648.
69. Patel DD, Goldberg RM: Cetuximab-associated infusion reactions:
pathology and management. Oncology (Williston Park) 2006,
20(11):1373-1382.
70. Chung CH, O’Neil BH: Infusion reactions to monoclonal antibodies for
solid tumors: immunologic mechanisms and risk factors. Oncology
(Williston Park) 2009, 23(2 Suppl 1):14-17.
71. George TJ Jr, Laplant KD, Walden EO, et al: Managing cetuximab
hypersensitivity-infusion reactions: incidence, risk factors, prevention,
and retreatment. J Support Oncol 2010, 8(2):72-77.
72. Chung CH: Managing premedications and the risk for reactions to
infusional monoclonal antibody therapy. Oncologist 2008, 13(6):725-732.
73. Saif MW, Syrigos KI, Hotchkiss S, et al: Successful desensitization with
cetuximab after an infusion reaction to panitumumab in patients with
metastatic colorectal cancer. Cancer Chemother Pharmacol 2009,
65(1):107-112.
74. Commins SP, James HR, Kelly LA, et al: The relevance of tick bites to the
production of IgE antibodies to the mammalian oligosaccharide
galactose-alpha-1,3-galactose. J Allergy Clin Immunol 2011,
127(5):1286-1293.
75. Chalaire KC, Kim TK, Garcia-Rodriguez H, Mulenga A: Amblyomma
americanum (L.) (Acari: Ixodidae) tick salivary gland serine protease
inhibitor (serpin) 6 is secreted into tick saliva during tick feeding. J Exp
Biol 2011, 214(Pt 4):665-673.
Saleh et al. Clinical and Molecular Allergy 2012, 10:5
http://www.clinicalmolecularallergy.com/content/10/1/5
Page 10 of 11
76. Masters EJ, Grigery CN, Masters RW: STARI, or Masters disease: Lone Star
tick-vectored Lyme-like illness. Infect Dis Clin North Am 2008,
22(2):361-376, viii.
77. Bircher AJ, Scherer HK: Drug hypersensitivity reactions: Inconsistency in
the use of the classification of immediate and nonimmediate reactions.
J Allergy Clin Immunol 2011, 129(1):263-264.
78. Thien FC: 3. Drug hypersensitivity. Med J Aust 2006, 185(6):333-338.
79. Gruchalla RS: 10. Drug allergy. J Allergy Clin Immunol 2003, 111(2 Suppl):
S548-S559.
80. Lewis MA, Hendrickson AW, Moynihan TJ: Oncologic emergencies:
Pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin
2011, [Epub ahead of print].
81. Salit RB, Bishop MR: The evolving world of tumor lysis syndrome.
Oncology (Williston Park) 2011, 25(4):378-380.
82. Howard SC, Jones DP, Pui CH: The tumor lysis syndrome. N Engl J Med
2011, 364(19):1844-1854.
83. Barbaud A, Granel F, Waton J, Poreaux C: How to manage hypersensitivity
reactions to biological agents? Eur J Dermatol 2011, 21(5):667-674.
84. Nagy G, Lukacs K, Sziray A, et al: Adverse events during biological
therapy-focusing on dermatological side-effects. Orv Hetil 2011,
152(6):212-220.
85. van Bueren JJ, Rispens T, Verploegen S, et al: Anti-galactose-alpha-1,3-
galactose IgE from allergic patients does not bind alpha-galactosylated
glycans on intact therapeutic antibody Fc domains. Nat Biotechnol 2011,
29(7):574-576.
86. Heun J, Holen K: Treatment with panitumumab after a severe infusion
reaction to cetuximab in a patient with metastatic colorectal cancer: a
case report. Clin Colorectal Cancer 2007, 6(7):529-531.
87. Nielsen DL, Pfeiffer P, Jensen BV: Six cases of treatment with
panitumumab in patients with severe hypersensitivity reactions to
cetuximab. Ann Oncol 2009, 20(4):798.
88. Power DG, Shah MA, Asmis TR, Garcia JJ, Kemeny NE: Safety and efficacy
of panitumumab following cetuximab: retrospective review of the
Memorial Sloan-Kettering experience. Invest New Drugs 2010,
28(3):353-360.
89. Restani P, Ballabio C, Cattaneo A, et al: Characterization of bovine serum
albumin epitopes and their role in allergic reactions. Allergy 2004,
59(Suppl 78):21-24.
90. Fiocchi A, Restani P, Riva E, et al: Meat allergy: II-Effects of food
processing and enzymatic digestion on the allergenicity of bovine and
ovine meats. J Am Coll Nutr 1995, 14(3):245-250.
91. Fiocchi A, Restani P, Riva E, et al: Heat treatment modifies the
allergenicity of beef and bovine serum albumin. Allergy 1998,
53(8):798-802.
92. Han GD, Matsuno M, Ikeuchi Y, Suzuki A: Effects of heat and high-pressure
treatments on antigenicity of beef extract. Biosci Biotechnol Biochem 2002,
66(1):202-205.
93. Jackson J, Beveridge I, Chilton NB, Andrews RH: Distributions of the
paralysis ticks Ixodes cornuatus and Ixodes holocyclus in south-eastern
Australia. Aust Vet J 2007, 85(10):420-424.
94. Hall-Mendelin S, Craig SB, Hall RA, et al: Tick paralysis in Australia caused
by Ixodes holocyclus Neumann. Ann Trop Med Parasitol 2011,
105(2):95-106.
95. Campbell F, Atwell R, Fenning A, Hoey A, Brown L: Cardiovascular effects
of the toxin(s) of the Australian paralysis tick, Ixodes holocyclus, in the
rat. Toxicon 2004, 43(7):743-750.
96. Campbell FE, Atwell RB: Long QT syndrome in dogs with tick toxicity
(Ixodes holocyclus). Aust Vet J 2002, 80(10):611-616.
97. Miller MK: Massive tick (Ixodes holocyclus) infestation with delayed
facial-nerve palsy. Med J Aust 2002, 176(6):264-265.
98. Grattan-Smith PJ, Morris JG, Johnston HM, et al: Clinical and
neurophysiological features of tick paralysis. Brain 1997, 120(Pt
11):1975-1987.
99. Drover VA, Ajmal M, Nassir F, et al: CD36 deficiency impairs intestinal lipid
secretion and clearance of chylomicrons from the blood. J Clin Invest
2005, 115(5):1290-1297.
100. Nauli AM, Zheng S, Yang Q, et al: Intestinal alkaline phosphatase release
is not associated with chylomicron formation. Am J Physiol Gastrointest
Liver Physiol 2003, 284(4):G583-G587.
101. Nauli AM, Nassir F, Zheng S, et al: CD36 is important for chylomicron
formation and secretion and may mediate cholesterol uptake in the
proximal intestine. Gastroenterology 2006, 131(4):1197-1207.
102. Porter CJ, Trevaskis NL, Charman WN: Lipids and lipid-based formulations:
optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007,
6(3):231-248.
103. Miller CW, Krishnaswamy N, Johnston C, Krishnaswamy G: Severe asthma
and the omalizumab option. Clin Mol Allergy 2008, 6:4.
doi:10.1186/1476-7961-10-5
Cite this article as: Saleh et al.: Anaphylactic Reactions to
Oligosaccharides in Red Meat: a Syndrome in Evolution. Clinical and
Molecular Allergy 2012 10:5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Saleh et al. Clinical and Molecular Allergy 2012, 10:5
http://www.clinicalmolecularallergy.com/content/10/1/5
Page 11 of 11
